

Manninen Petri Mikael
 Form 4
 November 02, 2007

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
 Manninen Petri Mikael

2. Issuer Name and Ticker or Trading Symbol
 ENCORIUM GROUP INC [ENCO]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)
 UNIONINKATU 22
 (Street)

3. Date of Earliest Transaction
 (Month/Day/Year)
 11/01/2007

Director 10% Owner
 Officer (give title below) Other (specify below)

HELSINKI, H9 00130
 (City) (State) (Zip)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership Indirect Beneficial Ownership (Instr. 4)	
			Code	V	Amount	(A) or (D)	Price	
Common Stock, \$.001 per share	11/01/2007		J ⁽¹⁾		40,589	A	\$ 2.83 <u>(2)</u>	313,992 I managing director of NTGLT Pharma BVBA
Common Stock, \$.001 per share	11/01/2007		P		2,742	A	\$ 2.67	69,115 D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not

SEC 1474 (9-02)

required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Owned Following Transaction (Instr. 5)
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Manninen Petri Mikael UNIONINKATU 22 HELSINKI, H9 00130	X			

Signatures

/s/ Petri Mikael
Manninen 11/01/2007

**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Mr. Manninen is managing director of NTGLT Pharma BVBA ("NTGLT"). On November 1, 2007, NTGLT became entitled to receive an additional 40,589 shares of Encorium Group, Inc.'s ("Encorium") common stock pursuant to a "hold-back" provision contained in the Amended and Restated Combination Agreement dated July 6, 2006 (the "Agreement"), pursuant to which Encorium acquired all of the issued and outstanding stock of Remedium Oy ("Remedium") on November 1, 2006. The Agreement provides that the former stockholders of Remedium are entitled to receive additional shares of Encorium common stock, for no additional consideration, on the first anniversary of the closing of the business combination.

(2) The terms of the Agreement provide that for the purpose of determining the number of shares issuable pursuant to the hold-back provision, Encorium's common stock would be valued at \$2.83 per share, representing the price per share at which the former Remedium stockholders received Encorium shares upon the closing of the Agreement.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.